Impact of individual characteristics of an organism, pathological processes, and combined administration of medicinal products on their efficacy

Published: 05.09.2018

References:

• Archakov A.I. (1983) Oksigenazyi biologicheskih membran. 37-e Bahovskoe chtenie. Nauka, Moskva, 56 s.
• Bazhora Yu.I. (2003) Farmakohenetyka: dosiahnennia i perspektyvy. Druk, Odesa, 140 s.
• Baryisheva V.O., Ketova G.G. (2016) Personalizirovannaya meditsina: realizatsiya farmakogenetiki v praktike. Nepreryivnoe meditsinskoe obrazovanie i nauka, 11(1): 4–7.
• Belousov Yu.B., Gurevich K.G. (2005) Klinicheskaya farmakokinetika. Praktika dozirovaniya lekarstv: Spets. vyipusk serii «Ratsionalnaya farmakoterapiya». Litterra, Moskva, 288 s.
• Bobrova O.P., Shnayder N.A., Zyiryanov S.K. (2017) Molekulyarnaya diagnostika polimorfizma genov biotransformatsii opioidnyih analgetikov i ee rol v izuchenii modifikatsionnoy izmenchivosti obezbolivaniya v klinicheskoy onkologii. V kn.: Molekulyarnaya dIagnostika, T. 1. Farmakogenetika i farmakogenomika, s. 519–520.
• Volovikova O.N., Mihaylova E.I. (2012) Rol farmakogenetiki v razvitii personalizirovannoy meditsinyi pri zabolevaniyah vnutrennih organov (obzor literaturyi). Problemyi zdorovya i ekologii, 2(32): 13–18.
• Drogovoz S.M., Gudzenko A.P., Butko Ya.A., Drogovoz V.V. (2010) Pobochnoe deystvie lekarstv: Uchebnik-spravochnik. SIM, Harkov, 480 s.
• Zhuravleva M.V., Kukes V.G., Prokofev A.B. i dr. (2015) Effektivnost i bezopasnost primeneniya lekarstvennyih sredstv: znachenie i vozmozhnosti klinicheskoy farmakologii. Vedomosti Nauchnogo tsentra ekspertizyi sredstv meditsinskogo primeneniya, 2: 20–24.
• Meditsinskoe informatsionnoe agentstvo, Moskva, 656 s.
• Ivanov A.M., Kamilova T.A., Dovgopolyuk A.B., Abritalin E.Yu. (2010a) Farmakogenetika v psihiatrii: antidepressantyi. Vest. Ros. voen.-med. akad., 2: 201–210.
• Ivanov A.M., Kamilova T.A., Dovgopolyuk A.B., Abritalin E.Yu. (2010b) Farmakogenetika v psihiatrii: neyroleptiki. Ros. voen.-med. akad., 3: 238–245.
• Komarov A.L. (2015) Otsenka chuvstvitelnosti k klopidogrelu: sovremennoe sostoyanie problemyi. Aterotromboz, 2: 95–106.
• Korzhov V.I., Zhadan V.N., Korzhov M.V. (2007) Rol sistemyi glutationa v protsessah detoksikatsii i antioksidantnoy zaschityi. Zhurn. AMN UkraYini, 13(1): 3–19.
• Kravchenko I.A. (2005) Farmakohenomika z osnovamy farmakohenetyky: Navch. pos. Astroprynt, Odesa, 144 s.
• Lazoryshynets V.V., Khobzei M.K., Mariievskyi V.F. ta in. (2011) Antybiotykorezystentnist klinichnykh shtamiv Enterobacter spp. v khirurhichnykh statsionarakh Ukraini v 2010 r. Liky Ukrainy, 1(5): 34–38.
• Mariievskyi V.F., Salmanov A.H., Khobzei N.K., Zozulia Y.S. (2011) Antybiotykorezystentnist klinichnykh shtamiv Enterococcus faecalis u khirurhichnykh statsionarakh Ukrainy v 2010r. Ukr. med. chasop., 3(83): 119–122.
• Matvieieva O., Yaichenia V. (2014) Otsutstvye эffektyvnosty lekarstvennoho sredstva yly medytsynskaia oshybka? Medychna hazeta Ukrainy «Vashe zdorovia», s. 7–8.
• Maharin O.A., Maklyakov Yu.S., Zhenilo V.M. (2012) Polimorfizm genov sistemyi detoksikatsii ksenobiotikov i ego rol v biotransformatsii vnutrivennyih anestetikov. Biomeditsina, 1(1–3): 98–107.
• Melnik A.A. (2016) Primenenie farmakogenotipirovaniya i dozirovanie nekotoryih preparatov v urologii i nefrologii. Pochki, 1(15): 96–104.
• Panchyshyn Yu..M., Yakubenko Yu.P. (2011) Statyny: pliusy ta minusy. Rats. farmakoter., 1(18): 47–56.
• Posokhova K.A. (2017) Yak kharchuvatysia pry likuvanni varfarynom. farmakoter., 2(43): 12–17.
• Renki P.Dzh., Renki R.G., Dzhon E., Renki G.N. (2014) Vliyanie upakovki na stabilnost lekarstvennyih preparatov. tehnol. upak., 6(244): 62–65.
• Sadvakas A.S. (2014) Рharmacogenetics of drug transporters. Nauka 21 veka: voprosyi, gipotezyi, otvetyi, 4: 55–60.
• Salmanov A.H. (2015) Antymikrobna rezystentnist ta infektsii, asotsiiovani z medychnoiu dopomohoiu v Ukraini. Epidemiolohichnyi zvit multytsentrovoho doslidzhennia (2010–2014 rr.). Ahshrar Media hrup, Kyiv, 452 s.
• Samura B.A. (red.) (2009) Zahalna farmakokinetyka. TDMU, Ternopil, 356 s.
• Sidorenko I.A., Galaeva Ya.Yu., Naletov S.V., Konyisheva N.V. (2017) Farmakogenetika i farmakoterapiya: obschie voprosyi. Un-tetskaya klinika, 12(1): 89–93.
• Skakun N.P. (1981) Klinicheskaya farmakogenetika. Zdorovia, Kyiv, 200 s.
• Skakun N.P., Saratikov A.S., Oleynik A.N., Vengerovskiy A.I. (1985) Etilovyiy alkogol (farmakokinetika, vzaimodeystvie s lekarstvami, gepatotoksichnost). Izd-vo Tomsk. un-ta, Tomsk, 135 s.
• Syichev D.A., Ignatev I.V., Emelyanov N.V. i dr. (2009) Farmakogeneticheskoe testirovanie: pervyie shagi v realnoy klinicheskoy praktike i problemyi standartizatsii. Problemyi standartizatsii v zdravoohranenii, 1: 43–55.
• Tashenova A.I. (2010) Transportnaya sistema glikoproteina-R i farmakokinetika lekarstvennyih sredstv. Biomeditsina, 1(4): 24–32.
• Feshchenko Yu.I., Humeniuk M.I., Denysov O.S. (2010) Antybiotykorezystentnist mikroorhanizmiv. Stan problemy ta shliakhy yii vyrishennia. Ukr. khimioter. zhurn., 23(1–2): 4–10.
• Chekman I.S., Posohova E.A., Beregovaya E.G. (1996) Mikrosomalnaya fermentnaya sistema organizma. Kiev–Zaporozhe, 80 s.
• Yakovleva O.O., Konovalova N.V., Kosovan A.I. ta in. (2011) Klinichna farmakohenetyka: Navch. posib. Nova knyha, Vinnytsia, 160 s.
• Cambria-Kiely J.A. (2002) Effect of soy milk on warfarin efficacy. Ann. Pharmacother., 36(12): 1893–1896.
• Ede M.C.M. (1973) Circadian rhythms of drug effectiveness and toxicity. Clin. Pharm. Therap., 14(6): 925–935.
• Food and Drug Administration US (2016) Table of pharmacogenomic biomarkers in drug labeling [2015-07-29].
• http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm 083378. htm
• Hider S.L., Bruce I.N., Thomson W. (2007) The pharmacogenetics of methotrexate. Rheumatology, 46(10): 1520–1524.
• Karlson B., Leijd B., Hellström K. (1986) On the influence of vitamin K‐rich vegetables and wine on the effectiveness of warfarin treatment. J. Inter. Med., 220(4): 347–350.
• Kempin S.J. (1983) Warfarin resistance caused by broccoli. New Engl. J. Med., 308(20): 1229–1230.
• Lee M., Schwartz R.N., Sharifi R. (1981) Warfarin resistance and vitamin K. Ann. Inter. Med., 94(1): 140–141.
• Martens H.J., De Goede P.N., Van Loenen A.C. (1990) Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am. J. Health-Syst. Pharm., 47(2): 369–373.
• Oliynyk O.V., Titov I.I., Pereviznyk B. (2016) Epidemiology of severe sepsis caused by severe craniocerebral trauma in Western Ukraine. Hospital surgery, 1(1): 44–50.
• Pedersen F.M., Hamberg O., Hess K., Ovesen L. (1991) The effect of dietary vitamin K on warfarin‐induced anticoagulation. J. Intern. Med., 229(6): 517–520.
• Seifi A., Mowla A., Vaziri M.M. et al. (2004) Insulin adsorbance to polyvinylchloride (PVC) surfaces of fluid container and infusion-set. Mid. East J. Anaesthesiol., 17(5): 975–981.
• Thompson C., Vital-Carona J., Faustino E.V.S. (2012) The effect of tubing dwell time on insulin adsorption during intravenous insulin infusions. Diabet. Technol. Therapeut., 14(10): 912–916.
• Weir S.J., Myers V.A., Bengtson K.D., Ueda C.T. (1985) Sorption of amiodarone to polyvinyl chloride infusion bags and administration sets. Am. J. Health-Syst. Pharm., 42(12): 2679–2683.
• World Health Organization (2001) WHO global strategy for containment of antimicrobial resistance: executive summary (WHO/CDS/CSR/DRS/2001.2).